Study of the Differential Activity of Thrombin Inhibitors Using Docking, QSAR, Molecular Dynamics, and MM-GBSA
暂无分享,去创建一个
Julio Caballero | Karel Mena-Ulecia | William Tiznado | Julio Caballero | W. Tiznado | Karel Mena-Ulecia
[1] P. Kollman,et al. Computational study of protein specificity: The molecular basis of HIV-1 protease drug resistance , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[2] Kenichi A Tanaka,et al. Blood Coagulation: Hemostasis and Thrombin Regulation , 2009, Anesthesia and analgesia.
[3] Julio Caballero,et al. Study of the Affinity between the Protein Kinase PKA and Peptide Substrates Derived from Kemptide Using Molecular Dynamics Simulations and MM/GBSA , 2014, PloS one.
[4] B. Tomczuk,et al. Structure-activity and crystallographic analysis of a new class of non-amide-based thrombin inhibitor. , 2000, Bioorganic & medicinal chemistry letters.
[5] Julio Caballero,et al. Docking and quantitative structure–activity relationship studies for sulfonyl hydrazides as inhibitors of cytosolic human branched-chain amino acid aminotransferase , 2009, Molecular Diversity.
[6] L. Lima,et al. Structure and Behavior of Human α-Thrombin upon Ligand Recognition: Thermodynamic and Molecular Dynamics Studies , 2011, PloS one.
[7] Mark R Player,et al. 2-(2-Chloro-6-fluorophenyl)acetamides as potent thrombin inhibitors. , 2007, Bioorganic & medicinal chemistry letters.
[8] Bernard R. Brooks,et al. New spherical‐cutoff methods for long‐range forces in macromolecular simulation , 1994, J. Comput. Chem..
[9] B. Tomczuk,et al. Oxyguanidines: application to non-peptidic phenyl-based thrombin inhibitors. , 2003, Bioorganic & medicinal chemistry letters.
[10] Jans H. Alzate-Morales,et al. Study of differences in the VEGFR2 inhibitory activities between semaxanib and SU5205 using 3D-QSAR, docking, and molecular dynamics simulations. , 2012, Journal of molecular graphics & modelling.
[11] J. Hirsh,et al. Translational Success Stories: Development of Direct Thrombin Inhibitors , 2012, Circulation research.
[12] Anil K. Saxena,et al. Profiling the Structural Determinants for the Selectivity of Representative Factor-Xa and Thrombin Inhibitors Using Combined Ligand-Based and Structure-Based Approaches , 2011, J. Chem. Inf. Model..
[13] P. Kollman,et al. Combined molecular mechanical and continuum solvent approach (MM-PBSA/GBSA) to predict ligand binding , 2000 .
[14] B. Tomczuk,et al. Non-peptidic phenyl-based thrombin inhibitors: exploring structural requirements of the S1 specificity pocket with amidines. , 2000, Bioorganic & medicinal chemistry letters.
[15] Jans H. Alzate-Morales,et al. Performance of the MM/GBSA scoring using a binding site hydrogen bond network-based frame selection: the protein kinase case. , 2014, Physical chemistry chemical physics : PCCP.
[16] Tingjun Hou,et al. Molecular dynamics and free energy studies on the wild-type and double mutant HIV-1 protease complexed with amprenavir and two amprenavir-related inhibitors: mechanism for binding and drug resistance. , 2007, Journal of medicinal chemistry.
[17] B. Tomczuk,et al. Amidinohydrazones as guanidine bioisosteres: application to a new class of potent, selective and orally bioavailable, non-amide-based small-molecule thrombin inhibitors. , 2000, Bioorganic & medicinal chemistry letters.
[18] B. Tomczuk,et al. Oxyguanidines. Part 2: Discovery of a novel orally active thrombin inhibitor through structure-based drug design and parallel synthesis. , 2004, Bioorganic & medicinal chemistry letters.
[19] Arthur M. Doweyko,et al. 3D-QSAR illusions , 2004, J. Comput. Aided Mol. Des..
[20] G. Klebe,et al. Enhancement of hydrophobic interactions and hydrogen bond strength by cooperativity: synthesis, modeling, and molecular dynamics simulations of a congeneric series of thrombin inhibitors. , 2010, Journal of medicinal chemistry.
[21] Laxmikant V. Kalé,et al. Scalable molecular dynamics with NAMD , 2005, J. Comput. Chem..
[22] Corwin Hansch,et al. An approach toward the problem of outliers in QSAR. , 2005, Bioorganic & medicinal chemistry.
[23] P. Carrupt,et al. Synthesis and biological evaluation of direct thrombin inhibitors bearing 4-(piperidin-1-yl)pyridine at the P1 position with potent anticoagulant activity. , 2013, Journal of medicinal chemistry.
[24] G. Klebe,et al. Knowledge-based scoring function to predict protein-ligand interactions. , 2000, Journal of molecular biology.
[25] Alexander D. MacKerell,et al. All-atom empirical potential for molecular modeling and dynamics studies of proteins. , 1998, The journal of physical chemistry. B.
[26] Julio Caballero,et al. Structural requirements of pyrido[2,3-d]pyrimidin-7-one as CDK4/D inhibitors: 2D autocorrelation, CoMFA and CoMSIA analyses. , 2008, Bioorganic & medicinal chemistry.
[27] Yujie Ren,et al. Design, synthesis and structural exploration of novel fluorinated dabigatran derivatives as direct thrombin inhibitors. , 2015, European journal of medicinal chemistry.
[28] W. L. Jorgensen,et al. Comparison of simple potential functions for simulating liquid water , 1983 .
[29] Matthew P. Repasky,et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. , 2004, Journal of medicinal chemistry.
[30] B. Tomczuk,et al. Discovery and clinical evaluation of 1-{N-[2-(amidinoaminooxy)ethyl]amino}carbonylmethyl-6-methyl-3-[2,2-difluoro-2-phenylethylamino]pyrazinone (RWJ-671818), a thrombin inhibitor with an oxyguanidine P1 motif. , 2010, Journal of medicinal chemistry.
[31] C. Kontogiorgis,et al. Quantitative structure -- activity relationships (QSARs) of thrombin inhibitors: review, evaluation and comparative analysis. , 2003, Current medicinal chemistry.
[32] M. Hämäläinen,et al. Compounds binding to the S2-S3 pockets of thrombin. , 2009, Journal of medicinal chemistry.
[33] I. Melnikova. The anticoagulants market , 2009, Nature Reviews Drug Discovery.
[34] B. Tomczuk,et al. Orally efficacious thrombin inhibitors with cyanofluorophenylacetamide as the P2 motif. , 2008, Bioorganic & medicinal chemistry letters.
[35] P. Shekelle,et al. Venous Thromboembolism Prophylaxis in Hospitalized Patients: A Clinical Practice Guideline From the American College of Physicians , 2011, Annals of Internal Medicine.
[36] G Klebe,et al. Three-dimensional quantitative structure-activity relationship analyses using comparative molecular field analysis and comparative molecular similarity indices analysis to elucidate selectivity differences of inhibitors binding to trypsin, thrombin, and factor Xa. , 1999, Journal of medicinal chemistry.
[37] Julio Caballero,et al. Protective mechanisms of adenosine 5′-monophosphate in platelet activation and thrombus formation , 2013, Thrombosis and Haemostasis.
[38] J. Correa-Basurto,et al. Exploring QSARs for inhibitory effect of a set of heterocyclic thrombin inhibitors by multilinear regression refined by artificial neural network and molecular docking simulations , 2012, Journal of enzyme inhibition and medicinal chemistry.
[39] Julio Caballero,et al. Binding Studies and Quantitative Structure–Activity Relationship of 3‐Amino‐1H‐Indazoles as Inhibitors of GSK3β , 2011, Chemical biology & drug design.
[40] B. Tomczuk,et al. In vitro evaluation and crystallographic analysis of a new class of selective, non-amide-based thrombin inhibitors. , 1998, Bioorganic & medicinal chemistry letters.
[41] S. Deswal,et al. Quantitative structure activity relationship studies of aryl heterocycle-based thrombin inhibitors. , 2006, European journal of medicinal chemistry.
[42] Alexander D. MacKerell,et al. CHARMM general force field: A force field for drug‐like molecules compatible with the CHARMM all‐atom additive biological force fields , 2009, J. Comput. Chem..
[43] H. Gohlke,et al. Free Energy Calculations by the Molecular Mechanics Poisson−Boltzmann Surface Area Method , 2012, Molecular informatics.
[44] Mirko Zimic,et al. Docking and quantitative structure–activity relationship studies for 3-fluoro-4-(pyrrolo[2,1-f][1,2,4]triazin-4-yloxy)aniline, 3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)aniline, and 4-(4-amino-2-fluorophenoxy)-2-pyridinylamine derivatives as c-Met kinase inhibitors , 2011, J. Comput. Aided Mol. Des..
[45] Bruce L. Bush,et al. Sample-distance partial least squares: PLS optimized for many variables, with application to CoMFA , 1993, J. Comput. Aided Mol. Des..